Furthermore, in the attempt to offer a novel therapeutic option for the AIP prophylaxis, we assessed the potential efficacy of a nutraceutical supplement, the insulin mimic alpha-lipoic acid (α-LA), which has been already tested for the treatment of metabolic disorders such as type 2 diabetes, turning out to be effective and safe at improving glucose handling, insulin sensitivity, and hepatic inflammation [18,19,20]. The gene discussed is INS; the disease is metabolic disease.